Jpmorgan Chase & CO Hille Vax, Inc. Transaction History

Jpmorgan Chase & CO

$1.22 Trillion
Q3 2024

A detailed history of Jpmorgan Chase & CO transactions in Hille Vax, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 14,027 shares of HLVX stock, worth $26,931. This represents 0.0% of its overall portfolio holdings.

Number of Shares

14,027

Previous 33,402 58.01%

Holding current value

$26,931

Previous $482,000 95.02%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 08, 2024	SELL	$1.58 - $14.42 $30,612 - $279,387	-19,375 Reduced 58.01%	14,027 $24,000
Q2 2024 Aug 12, 2024	SELL	$11.86 - $15.93 $162,126 - $217,763	-13,670 Reduced 29.04%	33,402 $482,000
Q1 2024 May 10, 2024	BUY	$14.15 - $19.75 $420,679 - $587,167	29,730 Added 171.43%	47,072 $782,000
Q4 2023 Feb 12, 2024	SELL	$10.35 - $17.11 $47,672 - $78,808	-4,606 Reduced 20.99%	17,342 $278,000
Q3 2023 Nov 14, 2023	BUY	$11.59 - $16.7 $49,014 - $70,624	4,229 Added 23.87%	21,948 $295,000
Q2 2023 Aug 11, 2023	BUY	$12.93 - $18.76 $36,333 - $52,715	2,810 Added 18.85%	17,719 $304,000
Q1 2023 May 18, 2023	BUY	$14.73 - $18.18 $196,984 - $243,121	13,373 Added 870.64%	14,909 $246,000
Q1 2023 May 11, 2023	SELL	$14.73 - $18.18 $144,530 - $178,382	-9,812 Reduced 86.46%	1,536 $25,000
Q4 2022 Feb 13, 2023	BUY	$13.52 - $21.46 $57,676 - $91,548	4,266 Added 60.24%	11,348 $190,000
Q3 2022 Nov 14, 2022	BUY	$10.5 - $22.01 $1,606 - $3,367	153 Added 2.21%	7,082 $121,000
Q2 2022 Aug 11, 2022	BUY	$8.7 - $20.18 $60,282 - $139,827	6,929 New	6,929 $76,000

Others Institutions Holding HLVX

# of Institutions

Shares Held

36.8M

Call Options Held

Put Options Held

View Full List

About HilleVax, Inc.

Ticker HLVX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 33,427,200
Market Cap $64.2M
Description
HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. It is developing HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company is headquartered in Boston, Massachusetts.

More about HLVX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Account

Jpmorgan Chase & CO Hille Vax, Inc. Transaction History